WeVote
Log In

Bill

Bill

HR 3010

No Handouts for Drug Advertisements Act

119th Congress Introduced by Angie Craig and 2 co-sponsors

HR 3010 prohibits federal funding for drug advertisements, aiming to reduce aggressive marketing and promote informed healthcare decisions for consumers and providers.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 3010

Summary of HR 3010 - No Handouts for Drug Advertisements Act

Bill Overview

Bill Number: HR 3010
Title: No Handouts for Drug Advertisements Act
Status: Introduced in House
Introduced Date: April 24, 2025
Classification: Bill

Purpose and Intent

The No Handouts for Drug Advertisements Act aims to eliminate government funding for drug advertisements. The bill seeks to address concerns regarding the influence of pharmaceutical advertising on public health and healthcare costs. By prohibiting the use of taxpayer dollars for these advertisements, the legislation intends to promote more responsible marketing practices within the pharmaceutical industry.

Key Provisions

  • Prohibition of Funding: The bill would prohibit federal funds from being used to support or promote drug advertisements. This includes any direct or indirect financial assistance for marketing campaigns related to pharmaceuticals.
  • Regulatory Oversight: The bill may establish guidelines for monitoring and enforcing compliance among pharmaceutical companies regarding advertising practices.
  • Public Awareness Campaigns: The legislation could encourage the development of public health campaigns that focus on educating consumers about medications without the influence of pharmaceutical advertising.

Affected Parties

  • Pharmaceutical Companies: The primary impact will be on pharmaceutical companies that rely on government funding for advertising. They may need to adjust their marketing strategies to comply with the new regulations.
  • Healthcare Providers: Providers may experience changes in how medications are marketed to them, potentially leading to a shift in prescribing practices.
  • Consumers: Patients may benefit from reduced exposure to aggressive drug marketing, potentially leading to more informed healthcare decisions.

Legislative Process

  • Introduced: The bill was introduced in the House on April 24, 2025.
  • Committee Referral: It has been referred to the House Committee on Ways and Means for further consideration and discussion.
  • Companion Bill: There is a related companion bill, S 1785, which is being considered in the Senate.

Conclusion

The No Handouts for Drug Advertisements Act represents a significant step towards regulating pharmaceutical advertising practices and promoting public health. By eliminating government funding for drug advertisements, the bill seeks to foster a more transparent and responsible approach to medication marketing. As the bill progresses through the legislative process, its implications for the pharmaceutical industry, healthcare providers, and consumers will become clearer.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.